Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
NGHIÊN CỨU LÂM SÀNG Issue: Số 106 năm 2023 TIM MẠCH DỰ PHÒNG BỆNH MẠCH VÀNH

LDL-C treatment goals achievement in acute coronary syndrome patients undergoing percutaneous coronary intervention in Quang Tri Provincial General Hospital

Nguyễn Hữu Đức: Bệnh viện Đa khoa tỉnh Quảng Trị; Hoàng Anh Tiến: Trường Đại học Y Dược Huế; Bùi Duy Hà: Bệnh viện Đa khoa tỉnh Quảng Trị; Nguyễn Nhật: Bệnh viện Đa khoa tỉnh Quảng Trị; Phan Cao Sang: Bệnh viện Đa khoa tỉnh Quảng Trị;
Published: August 1, 2023
Views: 161

Abstract

Objective: ​​Lipid goal attainment in post‐acute coronary syndrome patients undergoing percutaneous coronary intervention and ​​related factors.

Subjects  and  methods: A cross-sectional descriptive study on 400 patients with a recent acute coronary syndrome who had undergone percutaneous coronary intervention at Quang Tri General Hospital, followed up and re-examined at Quang Tri General Hospital, the duration of intervention was after 3 months to 24 months (had been on lipid lowering therapy for 3 months or more).

Results: the rate of reaching the target LDL-C <1,4 mmol/l in subjects after PCI was 36,8%. the rate of LDL-C reaching the target reduction >50% compared to the time of admission was 36,8%. The ratio of LDL-C decreased by >50% and reached <1,4 mmol/l was 24,8%. There was no significant effect of high potency statins on LDL-C goal attainment. Among patients who did not reach the LDL-C goal with high-intensity statins, the addition of Eztimibe helped 19,2% to achieve the goal LDL-C <1,4 mmol/l. In the group of patients with diabetes, the rate of reaching the LDL-C goal <1,4 mmol/l was higher (33.8%) than without diabetes (19.3%) with p <0,05. The rate of reaching the target Non-HDL <2,2 mmol/l and triglycerides <1,7 mmol/l were 70,3% and 60,5% respectively. Although having limitations, this study shows that the guideline-recommended LDL-C goal attainment rate is still suboptimal in a real-world setting.

References

1.
Roth G.A., Mensah G.A., et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J. Am. Coll. Cardiol. 2020, 76, 2982–3021.
2.
Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors. J. Am. Coll. Cardiol. 2019, 74, 2529–2532.
3.
Baigent C, Keech A, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366, 1267–1278.
4.
Schwartz GG, Steg PG, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N. Engl. J. Med. 2018, 379, 2097–2107.
5.
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-477.
6.
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337.
7.
Park JE, Chiang, et al Lipid-lowering treatment in hypercholesterolaemic patients: The CEPHEUS Pan-Asian survey. Eur. J. Prev. Cardiol. 2012, 19, 781–794.
8.
Schwaab B, Zeymer U, et al Improvement of low-density lipoprotein cholesterol target achievement rates through cardiac rehabilitation for patients after ST elevation myocardial infarction or non-ST elevation myocardial infarction in Germany: Results of the PATIENT CARE registry. Eur. J. Prev. Cardiol. 2019, 26, 249–258.
9.
Friedewald WT, Levy RI, Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18, 499–502.
10.
Barrios V, Pintó X, Escobar C, Varona JF, Gámez JM. Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study. J. Clin. Med. 2023, 12, 3187.
11.
De Backer G, Jankowski P, Kotseva K,EUROASPIRE V Collaborators; et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019, 285, 135–146.
12.
Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-6.
13.
Ali Allahyari and others, Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study, European Heart Journal, Volume 41, Issue 40, 21 October 2020, Pages 39003909.
14.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary.

Files

Article Views161
Document Views2
Downloads0
Section NGHIÊN CỨU LÂM SÀNG
Category TIM MẠCH DỰ PHÒNG, BỆNH MẠCH VÀNH